Feedback
Benzodiazepines, Serum or Plasma, Quantitative
2010445
Ordering Recommendation

Optimize drug therapy and monitor patient adherence.

Mnemonic
BENZO SP
Methodology
Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Performed
Tue, Fri
Reported
1-5 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
 
Collect
Gray (sodium fluoride/potassium oxalate). Also acceptable: Plain red, green (sodium heparin), lavender (EDTA), or pink (K2EDTA). 
Specimen Preparation
Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 2 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 1 mL) 
Storage/Transport Temperature
Refrigerated. 
Unacceptable Conditions
Gel separator tubes. Plasma or whole blood collected in lt. blue (sodium citrate). Hemolyzed specimens. 
Remarks
 
Stability
After separation from cells: Ambient: 1 week; Refrigerated: 2 weeks; Frozen: 3 years (Avoid repeated freeze/thaw cycles) 
Reference Interval
Effective November 16, 2015
Drugs CoveredCutoff Concentrations
Alprazolam5 ng/mL
Alpha-hydroxyalprazolam5 ng/mL
Clonazepam5 ng/mL
Chlordiazepoxide20 ng/mL
7-aminoclonazepam5 ng/mL
Diazepam5 ng/mL
Lorazepam20 ng/mL
Alpha-hydroxymidazolam20 ng/mL
Midazolam20 ng/mL
Nordiazepam20 ng/mL
Oxazepam20 ng/mL
Temazepam20 ng/mL

Interpretive Data
Methodology: Quantitative Liquid Chromatography-Tandem Mass Spectrometry.

Positive cutoff:
20 ng/mL unless specified below:
Diazepam 5 ng/mL
Alprazolam 5 ng/mL
Alpha-hydroxyalprazolam 5 ng/mL
Clonazepam 5 ng/mL
7-aminoclonazepam 5 ng/mL

For medical purposes only; not valid for forensic use.

Identification of specific drug(s) taken by specimen donor is problematic due to common metabolites, some of which are prescription drugs themselves. The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, or limitations of testing. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

Compliance Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note
CPT Code(s)
80346 (Alt code: G0480)
Components
Component Test Code*Component Chart NameLOINC
2010447Diazepam, S/P, Quant3548-5
2010448Nordiazepam, S/P, Quant3537-8
2010449Oxazepam, S/P, Quant59730-2
2010450Temazepam, S/P, Quant10343-2
2010451Lorazepam, S/P, Quant3724-2
2010452Alprazolam, S/P, Quant3312-6
2010453Alpha-hydroxyalprazolam, S/P, Quant27921-6
2010454Clonazepam, S/P, Quant3494-2
20104557-aminoclonazepam, S/P, Quant28059-4
2010459Midazolam, S/P, Quant3821-6
2012676Chlordiazepoxide, S/P, Quant3457-9
2012677Alpha-hydroxymidazolam, S/P, Quant69797-9
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases